# Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia

> **NCT00020800** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** fludarabine phosphate

## Key facts

- **NCT ID:** NCT00020800
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2003-04
- **Final completion:** —
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2013-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00020800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00020800, "Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00020800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*